Cheap Broker Fees
Cynata Therapeutics Limited is a biotechnology business based in Australia. Cynata Therapeutics shares (CYP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Cynata Therapeutics's stock price has had significant negative movement.
Its last market close was A$0.615, which is 43.06% down on its pre-crash value of A$1.08 and 6.03% up on the lowest point reached during the March crash when the stocks fell as low as A$0.58.
If you had bought A$1,000 worth of Cynata Therapeutics stocks at the start of February 2020, those stocks would have been worth A$581.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth A$572.09.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||A$0.62|
|52-week range||A$0.47 - A$0.93|
|50-day moving average||A$0.57|
|200-day moving average||A$0.56|
|Wall St. target price||A$2.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||A$-0.06|
|1 week (2021-10-11)||0.82%|
|1 month (2021-09-17)||8.85%|
|3 months (2021-07-16)||20.59%|
|6 months (2021-04-16)||2.50%|
|1 year (2020-10-16)||-26.35%|
|2 years (2019-10-18)||-54.10%|
|3 years (2018-10-18)||1.25|
|5 years (2016-10-18)||8.85%|
|Revenue TTM||A$1.5 million|
|Gross profit TTM||A$1.5 million|
|Return on assets TTM||-19.85%|
|Return on equity TTM||-34.05%|
|Market capitalisation||A$90.3 million|
TTM: trailing 12 months
We're not expecting Cynata Therapeutics to pay a dividend over the next 12 months.
Cynata Therapeutics's shares were split on a 1:20 basis on 30 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cynata Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cynata Therapeutics shares which in turn could have impacted Cynata Therapeutics's share price.
Over the last 12 months, Cynata Therapeutics's shares have ranged in value from as little as A$0.47 up to A$0.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cynata Therapeutics's is 0.3281. This would suggest that Cynata Therapeutics's shares are less volatile than average (for this exchange).
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. .
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.